Journal of Bone and Mineral Research· 2015Q1
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
- 664citations
- Q1SCImago
- 2015year
Short summary
A 2015 ASBMR task force suggests reassessing bisphosphonate (BP) therapy duration after 5 years (oral) or 3 years (IV) and considering drug holidays for low-risk patients, while continuing treatment up to 10 years (oral) or 6 years (IV) for high-risk individuals.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Orthopedics and Sports Medicine
Orthopedics and Sports MedicineMedicine